Search clinical trials for: Venetoclax, Azacitidine

Total 1266 results

M.D. Anderson Cancer Center

Recruiting

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
University of Florence

Active, not recruiting

Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients (FLO_CC-486-)

MDS | CMML

Italy
Celgene

Completed

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

Canada, United States, Taiwan, France, Spain, Greece, Italy, Singapore, Tunisia
Patrick Stiff

Recruiting

Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS

Myelodysplastic Syndrome MDS | Acute Myelogenous Leukemia AML

United States
Stichting Hemato-Oncologie voor Volwassenen Nederland
German CLL Study Group; Nordic CLL Study Group

Recruiting

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL (AETHER)

CLL/SLL

Netherlands, Denmark, Belgium, Germany
Dana-Farber Cancer Institute
AbbVie

Completed

Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia

Waldenstrom Macroglobulinemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation

Completed

Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant

Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Secura Bio, Inc.

Active, not recruiting

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Hodgkin Lymphoma | Non Hodgkin Lymphoma | Myeloma | Lymphocytic Leukemia

United States
University of Utah
Celgene

Completed

A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia

United States
AbbVie
Genentech, Inc.

Completed

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma

United States, Australia
Hannover Medical School

Recruiting

Venetoclax Registry (VENreg)

Acute Myeloid Leukemia

Germany
Sanjay Mohan
AbbVie; Karyopharm Therapeutics Inc

Active, not recruiting

Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Non-Hodgkin's Lymphoma | Diffuse Large B-cell Lymphoma

United States
Dana-Farber Cancer Institute
AbbVie

Active, not recruiting

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
Cyclacel Pharmaceuticals, Inc.
M.D. Anderson Cancer Center

Completed

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

AML | MDS

United States
Curis, Inc.
The Leukemia and Lymphoma Society

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Lymphoma | Refractory Lymphoma | Relapsed Lymphoma | Relapsed and/or Refractory Lymphoma | Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL) | Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Double-hit Lymphoma (DHL) | Triple-hit Lymphoma... and other conditions

United States
Peking Union Medical College Hospital

Recruiting

Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma

T-cell Lymphoma

China
Yale University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Withdrawn

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

Acute Myeloid Leukemia

United States
Celgene

Active, not recruiting

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Neoplasms | Hematologic Malignancies | Hematologic Neoplasm

United Kingdom, United States
Andrew Dinardo
Bristol-Myers Squibb

Withdrawn

Azacytidine During Anti-tuberculosis Therapy (AZA)

Tuberculosis, Pulmonary

United States
Wuhan Union Hospital, China

Not yet recruiting

A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score

Myelodysplastic Syndromes
Johns Hopkins All Children's Hospital

Recruiting

Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Juvenile Myelomonocytic Leukemia | Mixed Phenotype Acute Leukemia

United States
Daiichi Sankyo, Inc.

Terminated

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Jonsson Comprehensive Cancer Center
Celgene Corporation; CTI BioPharma

Terminated

Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States
Synphora AB

Unknown

Latanoprost for the Treatment of Menière's Disease

Menière's Disease

Sweden
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) (Captivate)

Leukemia | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Italy, New Zealand, Poland, Spain
Aprea Therapeutics

Terminated

APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) (R/R)

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States
The First Affiliated Hospital of Xiamen University
Shanxi Province Cancer Hospital; Sun Yat-sen University; Jiangsu Provincial People... and other collaborators

Recruiting

AZA Combined With RCHOP in P53-mutated DLBCL.

DLBCL - Diffuse Large B Cell Lymphoma | TP53

China
Seagen Inc.

Terminated

Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (CASCADE)

Acute Myeloid Leukemia

Korea, Republic of, United States, Spain, Belgium, Germany, Czechia, Hungary, Taiwan, France, Israel, Italy, United Kingdom, Australia, Austria, Poland, Luxembourg
Mirati Therapeutics Inc.

Terminated

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

Hodgkin Lymphoma | Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)

United States
Delta-Fly Pharma, Inc.

Not yet recruiting

Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

United States
Ryvu Therapeutics SA

Recruiting

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML (RIVER-81)

Acute Myeloid Leukemia

Spain, France, Poland, Italy
Calithera Biosciences, Inc

Completed

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Large B-cell, Diffuse

United States, Canada, Germany
Celgene

Completed

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, United Kingdom, Australia, Poland, Spain, Belgium, Italy, Germany, France, Canada
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
French Innovative Leukemia Organisation
Acute Leukemia French Association

Recruiting

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (OGILAR)

AML, Adult | Relapsed Adult AML | Refractory AML | FLT3-TKD Mutation | FLT3-ITD

France
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia

Acute Myeloid Leukaemia

United States, Australia, France, Spain
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Lung Cancer | Prostate Cancer | Multiple Myeloma and Plasma Cell Neoplasm

United States
Weill Medical College of Cornell University
Epizyme, Inc.; Genentech, Inc.

Recruiting

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin | Follicular Lymphoma | Diffuse Large B Cell Lymphoma

United States
Paolo Ghia

Not yet recruiting

Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens (LymBIO)

Chronic Lymphocytic Leukemia
Curis, Inc.

Recruiting

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

Germany, United States, Spain, Israel, Czechia, Poland, France, Italy
Dana-Farber Cancer Institute
AbbVie

Recruiting

Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

Leukemia

United States
AbbVie

Active, not recruiting

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Acute Myeloid Leukemia | Cancer | Multiple Myeloma | Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

United States, Australia, Canada, Denmark, Greece, Hong Kong, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Portugal, Russian Federation, Spain, Turkey, Ukraine, United Kingdom, France, Taiwan, Austria, Belgium, Ireland, S...
Dana-Farber Cancer Institute
Bayer; AbbVie

Active, not recruiting

Copanlisib Plus Venetoclax in R/R DLBCL

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United States
Paolo Ghia

Active, not recruiting

Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (IMPROVE)

Chronic Lymphocytic Leukemia

Italy
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)

Lupus Erythematosus

United States, Germany, Mexico, Puerto Rico
Groupe Francophone des Myelodysplasies
AbbVie

Recruiting

Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) (AVENHIR)

Chronic Myeloid Leukemia

France
Hoffmann-La Roche

Completed

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

Leukemia, Myeloid, Acute

United States, Canada, France, Italy
Nordic Lymphoma Group

Active, not recruiting

Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma (VALERIA)

Relapsed Non Hodgkin Lymphoma

Norway, Sweden, Finland, Denmark
Janssen Cilag S.A.S.

Completed

A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab (PROUST)

Psoriatic Arthritis

France
AbbVie
Roche-Genentech

Completed

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

Non-Hodgkin's Lymphoma | Neuroblastoma | Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Malignancies

United States, Australia, Canada, France, Germany, Netherlands, Switzerland, United Kingdom

Search clinical trials for: Venetoclax, Azacitidine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations